CapitalBio and Fetal Chromosomal Aneuploidy: Cutting-edge Exploration and Technological Innovation

CapitalBio is one of the leading companies in China's biotechnology field. With strong scientific research strength and technological innovation, CapitalBio has rapidly developed into a leading international biotechnology company, providing high-quality products and services for global biomedical research and clinical diagnosis.

Fetal Chrmoml Aneuploidy: A Major Issue for Life and Health

Under normal circumstances, the human body is a diploid with 23 pairs of 46 chromosomes. Fetal chrmoml aneuploidy is an abnormality in which two or more fetal chromosomes are missing or extra, but usually there is one extra chromosome, which makes the chromosomes no longer diploid and aneuploid, but presenting a fetal chrmoml aneuploidy abnormality. This abnormality may lead to a variety of birth defects, such as congenital heart disease, mental retardation, etc., seriously affecting the health and quality of life of the foetus.

NIPT Technology: The Innovative Power of Non-invasive Prenatal Screening

Fetal chrmoml aneuploidy non-invasive testing collects peripheral blood of pregnant women, extracts total free DNA, adopts new generation of high-throughput sequencing technology, and combines it with biological information analysis to calculate the relative content of fetal free DNA and arrive at the risk rate of fetal chromosomal abnormality. Because it does not require traumatic sampling and has high sensitivity and specificity, it has been increasingly valued by the clinic, and it can make the detection rate of fetal 21-trisomy syndrome reach 99%, and is applied to the clinic as a new, near-diagnostic level screening fetal chrmoml aneuploidy technology.NIPT technology has the advantages of non-invasive, accurate and rapid, and it has become one of the important means of prenatal diagnosis.

CapitalBio, as a leading biotechnology company, has also achieved significant results in the development and application of NIPT technology, which adopts the most advanced second-generation sequencing technology to comprehensively detect foetal chromosome aneuploidies, including the common 18-trisomy, 21-trisomy and 13-trisomy, etc. The technology is used to extract peripheral blood from pregnant women to screen for fetal chrmoml aneuploidy. By extracting fetal free DNA from the peripheral blood of pregnant women and combining it with bioinformatics analysis and data mining technology, CapitalBio's NIPT technology can accurately determine whether there is any chromosomal abnormality in the foetus, and provide timely and accurate diagnosis results for pregnant women and families.

CapitalBio's Contribution to Fetal Chrmoml Aneuploidy and NIPT Technology

CapitalBio's contribution in the field of fetal chrmoml aneuploidy and NIPT technology is mainly reflected in the following aspects:

Technological Innovation: CapitalBio continuously invests in research and development to promote the innovation and development of NIPT technology. The company adopts state-of-the-art sequencing technology and bioinformatics analysis methods to improve the accuracy and reliability of NIPT technology.

Product Development: CapitalBio has developed a series of high-quality prenatal diagnostic products based on NIPT technology. These products have the advantages of simple operation, accurate results and fast reporting, providing convenient and efficient diagnostic services for pregnant women and families.

Clinical application: CapitalBio's NIPT technology has been widely used in clinical practice, helping a large number of pregnant women and families detect fetal chromosomal abnormalities in a timely manner, avoiding unnecessary pain and loss.

Academic exchange and cooperation: CapitalBio actively participates in academic exchange and cooperation activities at home and abroad, and has established a wide range of cooperative relationships with renowned universities and research institutions at home and abroad. The company regularly organises activities such as academic seminars and training courses to promote the popularity and application of NIPT technology.

In conclusion, CapitalBio, as one of the leading companies in the field of biotechnology, has made remarkable achievements and contributions in fetal chrmoml aneuploidy and NIPT technology. The company will continue to devote itself to technological innovation and product research and development work to provide more high-quality and efficient products and services for global biomedical research and clinical diagnosis.